npj Parkinson s DiseaseNeurosciencePeer-reviewed journal article
MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity
Nanna Møller JenseniD, YuHong FuiD, Cristine BetzeriD, Hongyun LiiD, Sara ElfarrashiD, Ali ShaibiD, Donatus KrahiD, Zagorka ViticiD, Lasse ReimeriD, Hjalte GramiD, Vladimir L. BuchmaniD, Mark DenhamiD, Silvio O. RizzoliiD, Glenda Margaret HallidayiD, Poul Henning JenseniD
Abstract
Lewy pathology, consisting of Lewy bodies and Lewy neurites, is the pathological hallmark of synucle-inopathies such as Parkinsons disease and dementia with Lewy bodies, but it is generally thought to represent late-stage pathological changes. In contrast, -synuclein oligomers are regarded as early-stage pathology, likely involved in disease progression and cellular toxicity. Oligomers, however, are not de-tected by standard immunohistochemistry but require specific detection techniques such as the proxim-ity ligation assay (PLA). Here, we describe the MJF-14 PLA, a new PLA towards aggregated -synuclein with unprecedented specificity, attained by the utilization of aggregate conformation-specific -synu-clein antibody MJFR-14-6-4-2 (hereafter MJF-14). Signal in the assay directly correlates with -synuclein aggregation in SH-SY5Y cells, as treatment with aggregation inhibitor ASI1D significantly lowers PLA sig-nal. In human cortical neurons, MJF-14 PLA detects pre-formed fibril-induced aggregation, especially prominent when using stealth PFFs invisible to the MJF-14 antibody. Co-labelling of MJF-14 PLA and pS129--synuclein immunofluorescence in post-mortem dementia with Lewy bodies cases showed that while the MJF-14 PLA reveals extensive non-inclusion pathology, it is not sensitive towards Lewy bodies. In Parkinsons disease brain, direct comparison of PLA and IHC with the MJF-14 antibody, combined with machine learning-based quantification, showed striking -synuclein pathology preceding the formation of conventional Lewy pathology. The majority of the PLA-revealed non-inclusion pathology was found in the neuropil, including some clearly located in the presynaptic terminals. With this work, we introduce an improved -synuclein aggregate PLA to uncover abundant non-inclusion pathology, which deserves future validation with multiple brain bank resources and in different synucleinopathies.
- organism: human
- assay: protein structure
- research focus: cell type annotation
- research focus: differential expression
- research focus: spatial domain detection
- approach: experimental assay
- Citations
- 18
- FWCI
- 4.82
- Field percentile
- top 4%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases
Nanna Møller Jensen, Zagorka Vitic, … Poul Henning Jensen·Acta NeuropathologicaPeer-reviewed·May 2, 2025
- Specific Detection of Endogenous S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay
Ryan Arlinghaus, Michiyo Iba, … Natalie Landeck·bioRxiv·Sep 28, 2021
- Large-scale visualisation of α-synuclein oligomers in Parkinson's disease brain tissue
Rebecca Andrews, Bin Fu, … Steven F. Lee·Nature Biomedical EngineeringPeer-reviewed·Oct 1, 2025
- Cortical synaptic vulnerabilities revealed in a α-synuclein aggregation model of Parkinson's disease
Saroj Kumar Sah, Andrew D. Sauerbeck, … Thomas Biederer·bioRxiv·Jun 20, 2024
- Structural basis of epitope recognition by anti-alpha synuclein antibodies MJFR14-6-4-2
I. Lieknina, Lasse Reimer, … Kaspars Tārs·npj Parkinson s DiseasePeer-reviewed·Oct 27, 2024
- Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein
Nolwazi Z. Gcwensa, Drèson L. Russell, … Laura A. Volpicelli‐Daley·Neurobiology of DiseasePeer-reviewed·Jul 5, 2024